Rare Disease Report

AHCF Impact Statement: Continuing the Momentum...one step at a time

OCTOBER 16, 2017
Greetings! Gratitude does not even come close to expressing how the Alternating Hemiplegia of Childhood Foundation (AHCF) feels about each of you; our donors, sponsors, supporters and volunteers. It is always a great honor to work with exceptional people who continuously help us move forward in finding a treatment and ultimately a cure for AHC. You are who make this foundation succeed in raising awareness and funding research.

Through your generosity, we put your donation dollars to work funding $250,000 to Vanderbilt and Northwestern Universities for the 5th phase of “Molecular Physiology and Pharmacology of ATP1A3 Mutations in AHC”; a generous donation from the Jake and Nina Kamin Foundation funded the creation of the mouse model with the gene mutation D801Y and a mouse model with the G947R mutation; and with an incredible anonymous benefactor, the AHCF began the project “AHC Proposal - 2017 Antibody Acceleration”. The  creation of specific  antibodies against the of ATP1A3  and  ATP1A2,  will  aid  in  accelerating research. These antibodies will be available for the researchers and scientific community next year.

Our Third Annual Impact Statement summarizes our accomplishments of 2016/2017. While we have been blessed with a solid financial outlook, some of these funds are earmarked for the coming year. We also look to the future knowing that we must continue to raise funds, raise awareness, and keep researchers and scien- tists working to help our children.

The AHCF will continue to fight along with all of you until our children are no longer affected by AHC. Our goal is and will forever be, to END AHC.

With appreciation and warm regards,

Lynn MacDonald Egan AHC Parent
AHCF President San Francisco, CA


Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2019 Rare Disease Communications. All Rights Reserved.